Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiol Therapeutics (CRDL) Payables (2020 - 2025)

Cardiol Therapeutics filings provide 3 years of Payables readings, the most recent being $6.9 million for Q4 2022.

  • On a quarterly basis, Payables rose 78.37% to $6.9 million in Q4 2022 year-over-year; TTM through Dec 2022 was $6.9 million, a 78.37% increase, with the full-year FY2022 number at $6.9 million, up 78.37% from a year prior.
  • Payables hit $6.9 million in Q4 2022 for Cardiol Therapeutics, up from $3.9 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $6.9 million in Q4 2022 to a low of $1.9 million in Q4 2020.
  • Median Payables over the past 3 years was $3.9 million (2021), compared with a mean of $4.2 million.
  • Biggest five-year swings in Payables: skyrocketed 103.78% in 2021 and later surged 78.37% in 2022.
  • Cardiol Therapeutics' Payables stood at $1.9 million in 2020, then skyrocketed by 103.78% to $3.9 million in 2021, then surged by 78.37% to $6.9 million in 2022.
  • The last three reported values for Payables were $6.9 million (Q4 2022), $3.9 million (Q4 2021), and $1.9 million (Q4 2020) per Business Quant data.